title: A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate.
abstract: The objective of this study was to find a new parameter to monitor bleeding tendency after dabigatran etexilate (Pradaxa) medication in Chinese nonvalvular atrial fibrillation patients. Blood samples of 231 nonvalvular atrial fibrillation patients were collected and five routine coagulation examinations (prothrombin time/International normalized ratio, activated partial thromboplastin time, fibrinogen assay, thrombin time and D-dimer) were assayed. After dabigatran etexilate administration, prolonged activated partial thromboplastin time and thrombin time were observed, especially TT. Derived parameter ΔTT (TT after dabigatran etexilate medication - TT before dabigatran etexilate medication) of bleeding patients was higher than nonbleeding patients (97.7 vs. 85.6 s, P = 0.038). When using ΔTT to distinguish patients with and without bleeding events, the cutoff value was 97.25 s, where sensitivity was 82.4% and specificity was 50.0%. The area under the curve was 0.786. TT is better than other routine coagulation parameters in monitoring the effect of dabigatran etexilate. ΔTT can distinguish bleeding patients from nonbleeding patients.
authors.affiliation: Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
authors.forename: Yun
authors.initials: Y
authors.lastname: Zhou
authors.forename: Guodong
authors.initials: G
authors.lastname: Rong
authors.forename: Lin
authors.initials: L
authors.lastname: Lu
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use*; D019540:Area Under Curve; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D015331:Cohort Studies; D000069604:Dabigatran / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012680:Sensitivity and Specificity
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D000069604:Dabigatran